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The eﬀect of candesartan, an angiotensin-II type-1 receptor antagonist, on the metabolic proﬁle and renal inﬂammation is
unclear. We evaluated this relationship by feeding male lean (LZ) and obese (OZ) Zucker rats chow or chow with candesartan
(23.5mg/kg·diet)for14weeks(n = 6–8/treatment/bodytype).Candesartanreducedserumtriglycerides,plasmacreatinine,urine
albumin, and renal cortical collagen and glycogen deposition in the OZ. An ELISA-based cytokine array revealed that candesartan
normalized elevated renal interleukin (IL)1-β and monocyte chemoattractant protein-1 (MCP-1) levels in OZ. Nonetheless,
candesartan impaired glucose tolerance, and did not lower blood insulin or glucose levels. Moreover, renal IL-1α,- 2 ,- 4 ,- 6a n d- 1 0
tumor necrosis factor-α, interferon-γ, were signiﬁcantly reduced in OZ relative to LZ, and increased by candesartan. Furthermore,
candesartan increased growth-regulated oncogene, transforming growth factor-β1 and IL-18 in OZ kidneys to a level higher than
LZ or untreated OZ. Candesartan did not aﬀect renal cytokine levels in LZ. Overall, candesartan attenuated renal disease and
improved renal function in OZ, despite mixed eﬀects on metabolic factors and cytokines. Reduced plasma triglycerides and/or
r enalMCP -1andIL -1β mayhavehadaroleinthisprotection.However,theseeﬀectswereclearlyindependentofanyimprovement
in glucose tolerance.
1.Introduction
Renal disease or nephropathy is a frequent complication
of the metabolic syndrome and a leading cause of end-
stage renal failure in type II diabetes [1]. Hypertension,
inﬂammation,insulinresistance,and/oranalteredmetabolic
proﬁle,includingpoorglycemiccontrolanddyslipidemiaare
among the several mechanisms or “risk factors” associated
with this disorder [2–9]. Elucidation of these mechanism(s)
is crucial in guiding the development of more eﬃcacious
therapies to combat renal disease, improve the quality of life
in this patient population, and assuage the societal burden of
the metabolic syndrome.
Angiotensin II (Ang II), a potent vasoconstrictor, and
mediator of oxidative stress and proliferative pathways in
tissue, is a strong candidate in modulating many of these risk
factors [10–12] .A n gI Ir a i s e sb l o o dp r e s s u r e[ 13], induces
insulin resistance[14, 15], and increases inﬂammation by
either directly activating immune cells or by producing
inﬂammatory mediators [16, 17]. Furthermore, clinical as
well as basic research studies have shown that treatment
with any of several available Ang II receptor blocker
(ARBs), compounds that bind antagonistically to the Ang II,
type I receptor (AT1R), results in renoprotection [18–21].
Candesartan (CAN), one such ARB, commonly prescribed
to lower blood pressure (BP), has clearly been shown to
improve renal function and attenuate renal disease [20, 21];
however the mechanism(s) underlying this protection is not
entirely clear.
T h eo b e s eZ u c k e rr a ti sam o d e lf o rh u m a nm e t a b o l i c
syndromewithassociatedrenaldisease[22,23].Onemanner
in which CAN would be expected to exert signiﬁcant reno-
protection is by lowering BP. We have already published
BP in response to chronic CAN therapy in the same2 Mediators of Inﬂammation
set of rats [24]. CAN treatment for 14 weeks resulted
in a marked and sustained fall in BP of approximately
20–30mm Hg, in both lean and obese rats[24]. ARBs
have also been demonstrated to reduce inﬂammation in
tissues, such as the pancreas, heart, brain, vasculature, and
adrenal gland [25–27], improve insulin sensitivity [28–
30], and activate PPAR-γ, an intracellular nuclear hormone
receptor involved in the regulation of carbohydrate and lipid
metabolism[31]. Therefore, the beneﬁcial actions of ARBs
on the kidney may extend well beyond their BP-lowering
actions.
In this report, we examine the eﬀects of chronic CAN
therapy on renal function and disease in obese and lean
Zucker rats. We determine whether attenuation of renal
inﬂammation and/or factors associated with the metabolic
syndrome may contribute to any observed renoprotective
eﬀects of CAN. We utilize a cytokine array to measure 14
cytokines/chemokines in the whole kidney homogenates of
treated rats. In addition, we measure certain indices of the
metabolic proﬁle including plasma triglycerides and glucose
tolerance. We hypothesize that chronic CAN therapy will
reduce renal inﬂammation (perhaps via improvement in
the metabolic status), in the obese Zucker rat, thus poten-
tially contributing to attenuation of renal disease in these
rats.
2. Methods
2.1. Animals Study Design. T h i r t y - t w om a l eZ u c k e rr a t s
(16 lean and 16 obese) were obtained from Charles River
Laboratories (Wilmington, MA). Rats were singly housed
in microﬁlter top, plastic cages with a normal 12-hour
light/dark cycle according to protocols approved by the
Georgetown Animal Care and Use Committee, an AAALAC
(Association forAssessmentand Accreditationof Laboratory
Animal Care, International) approved facility. At about 9
weeks of age, 8 rats from each body type were randomly
assigned to either ground control diet (Purina 5001 Rodent
Chow, Purina Mills, St. Louis, MO) solidiﬁed in agar with
70% water, or the same base diet with 23.5mg candesartan
cilexetil (Atacand, AstraZeneca Pharmaceuticals, Wilming-
ton, DE) incorporated per kg diet (wet weight). This resulted
in an approximate dose of 3-4 mg/kg · bw/day of CAN in
the treated rats. Rats were weighed weekly and fed diets and
received water ad libitum for 14 weeks. Urine was collected at
12 weeks in metabolic cages.
2.2. Glucose-Tolerance Test. A glucose tolerance test (GTT)
was given to all rats at 13 weeks to assess their ability to
rapidly regulate blood glucose (a function of insulin sensitiv-
ity). The test was performed as described previously[32, 33].
Brieﬂy,ratsweregivena50%dextrosesolution(3ml/kg·bw)
intraperitoneally. Glucose was measured in tail blood with
a glucometer (One-Touch, Lifescan, Johnson & Johnson)
after pricking the tail at 15, 30, 60, 90, and 120 minutes
postglucose administration. Blood glucose concentration
over time was plotted and the areas under the curves were
calculated and statistically compared.
2.3.KidneysandBloodCollection. Attheendofthe14weeks,
rats were deeply anesthetized with sodium pentobarbital and
the right kidney perfusion ﬁxed, as described previously
[34, 35], for histochemical analyses. Prior to perfusion, some
blood was collected into both K3-EDTA- and Na+-heparin-
containing vacutainer tubes (Becton-Dickinson, Franklin
Lakes, NJ). Immediately after euthanization, the left kidney
was removed and processed as a whole kidney homogenate
for the analysis of protein levels.
2.4. Plasma and Urine Analyses. Plasma insulin levels were
analyzed in blood collected at euthanization by a radioim-
munoassay, as previously described [36]. Triglycerides and
urine albumin were analyzed by colorimetric assays (Sigma,
St. Louis, MO and Exocell, Philadelphia, PA, resp.). Plasma
creatinine was determined by the Jaﬀe rate method (Creati-
nine Analyzer 2, Beckman Diagnostics Systems Group, Brea,
CA).
2.5. Histochemical Staining. After ﬁxation with 4% parafor-
maldehyde, the right kidney was processed to paraﬃn, sec-
tioned at 4 μm, and stained with periodic acid-Schiﬀ’s (PAS;
for demonstration of glycogen deposition) to determine
glomerulosclerosis, which is deﬁned as thickening of the
basement membrane and mesangial expansion) or Masson’s
trichrome (for demonstration of collagen deposition) to
determine tubulointerstitial ﬁbrosis, which is deﬁned as
tubular atrophy or dilatation, deposition of extracellular
matrix, and interstitial ﬁbroblast proliferation [37].
2.6. Cytokine Proﬁle Using an ELISA-Based Cytokine Array.
Levels of monocyte chemoattractant protein-1 (MCP-
1), interleukins (IL)-1β,- 1 α, -2, -6, -5, -4, -10, -18,
-12p70, tumor necrosis factor-α (TNF-α), interferon-γ
(INF-γ), growth-regulated oncogene (GRO-KC), and gran-
ulocyte macrophage colony-stimulating-factor (GM-CSF)
were determined in the whole kidney homogenates using a
rat cytokine/chemokine LINCOplex premixed 96-well plate
assay (Millipore, St. Charles, MO, catalog no. RCYTO-80K-
PMX).
2.7. Western Blotting. Western blotting was performed as
previously described [32] on whole kidney homogenates
to evaluate the eﬀects of body type and therapy on
endothelial nitric oxide synthase (eNOS, NOS3) and TGF-
β1 (transforming growth factor using commercially avail-
able antibodies: polyclonal NB100-91995 (TGF-β1, Novus
Biologicals, Littleton, CO), and monoclonal 610297 (eNOS,
Transduction Laboratories, San Diego, CA).
2.8. Statistics. To determine the overall eﬀects of CAN
treatment and body type on variables of interest, data were
analyzed by two-way (body type × treatment) analysis of
variance (ANOVA). The diﬀerence between individual pairs
of means was analyzed by unpaired t-test. If data were
nonparametric, not normally distributed, or variances were
diﬀerent, we used the Mann-Whitney rank sum test (Sigma
Stat, Chicago, IL). P<. 05 was considered signiﬁcant forMediators of Inﬂammation 3
all analyses. Among the 14 cytokines analyzed in the array,
6, that is, IL-1α, IL-4, IL-10, IL-12p70, IFN-γ and TNF-α,
were below detection levels in the untreated obese group, as
well as in some treated obese rats (1 or 2 out of 6). Thus
the statistical analyses for these 6 cytokines were done in a
diﬀerent way; that is, cytokine levels were categorized (one
category was “undetectable”), and a t-test (Rank Test) on
categoricalassignmentswasdone.Theother8cytokineswere
analyzed by standard unpairedt-test as continuous variables.
3. Results
3.1. Chronic Candesartan Treatment Improves the Indices of
Renal Function and Reduces Pathology. Obese Zucker rats
had signiﬁcantly higher levels of plasma creatinine (Fig-
ure 1(a)) and urine albumin excretion (Figure 1(b)), relative
to lean age-mates, indicating impaired renal function and
advancing renal disease. Both plasma creatinine and urine
albumin were markedly reduced in the obese rats treated
with CAN. CAN also resulted in a signiﬁcant reduction in
these two parameters in the lean rats, although the reduction
was of considerably lower magnitude.
In addition to improving renal function, chronic CAN
therapy attenuated renal pathology in obese rats as revealed
by histochemical staining. Untreated obese rats demon-
strated marked renal pathology as indicated by features
of glomerulosclerosis and tubulointerstitial ﬁbrosis in their
kidney sections relative to lean rats (Figure 2). Chronic CAN
attenuated these pathological features. As shown in Figure 2,
Masson trichrome-stained paraﬃn sections revealed heavy
deposition of collagen in the interstitial spaces (light-blue
staining,Figure2(a)andenlargedlumensoftherenaltubules
in untreated obese rats only. Similarly, mesangial expansion
(arrows) and hyaline casts in the renal tubules were found
only in untreated obese rats’ kidney by periodic Schiﬀ’s
staining (Figure 2(b)). There was no apparent eﬀect of the
chronic CAN therapy on renal histology in the lean rats.
3.2. Candesartan Has an Opposite Eﬀect in Lean and Obese
Rats with Regard to Water Intake and Urine Volume. As
expected, obese rats gained signiﬁcantly more weight by
the end of the study (Table 1). CAN treatment did not
signiﬁcantlyaﬀectweightgain,althoughtherewasatrendfor
weight gain to be less in the obese CAN rats. Absolute water
intake and urine volumes were higher in obese rats; however,
when normalized by kidney weight, urine volume was lower
in obese control rats and corrected (to lean levels) by CAN.
In contrast, CAN signiﬁcantly decreased urine volume in
lean rats, so that there was a signiﬁcant interaction between
termsinthe2-wayANOVA.Therewasalsoastrongtrendfor
decreased water intake in these treated lean rats (P = .064,
unpaired t-test between Lean Control and Lean CAN).
3.3. Candesartan Reduced Serum Triglyceride Levels. Serum
triglycerides were signiﬁcantly increased in obese rats related
to lean (Table 1). Candesartan treatment signiﬁcantly
reduced triglyceride levels in obese rats (to a level only 46%
of the untreated obese level), and to more modest extent in
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Figure 1: Plasma creatinine (a) and urinary albumin excretion
(b) in candesartan-treated (CAN) or -untreated (c) lean and
obese rats at the end of 14 weeks of treatment (n = 8p e r
body type/treatment). Obese had signiﬁcantly increased albumin
excretion and higher plasma creatinine relative to lean groups;
CANtreated groups were signiﬁcantly diﬀerent from control by 2-
way ANOVA (P<. 05). ∗ indicates a signiﬁcant diﬀerence (P<. 05)
fromleancontrolmeanand#fromobesecontrolmeanbyunpaired
t-test.
the lean(to 75% of the untreated leanlevel). Levels in treated
obese rats were still on average 85% higher than lean control.
3.4. Candesartan Has an OppositeEﬀect in Lean and Obese
Rats with Regard to Glucose Tolerance. Obese rats demon-
stratedsigniﬁcantlyslowerplasmaglucoseclearance(glucose
tolerance, measured at 13 weeks), in response to intraperi-
toneally administered glucose (3ml/kg·bw), relative to lean
rats (Figure 3(a)). Unexpectedly, CAN treatment further
worsened this impairment, as demonstrated by signiﬁcantly
higher area under the curve (AUC) for plasma glucose levels
over time in CAN-treated obese rats relative to untreated
obese. In lean rats, however, CAN signiﬁcantly improved
glucose tolerance. This led to a signiﬁcant interaction
between body type and treatment by 2-way ANOVA.4 Mediators of Inﬂammation
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Figure 2: Renal cortical pathology: glomerulosclerosis and tubulointerstitial ﬁbrosis were assessed in periodic acid Schiﬀ and Masson’s
trichrome-stained paraﬃns e c t i o n s( 4μm sections, 6 sections/kidney were analyzed) from Zucker rats (Lean or obese) treated with (+CAN)
or without candesartan (−CAN) (n = 3/bodytype/treatment). (a) Masson trichrome-stained paraﬃn sections showing enlarged lumens of
the renal tubules and heavy deposition of collagen in the interstitial spaces (light-blue staining, arrows) in untreated rats only. (b) Periodic
acid Schiﬀ’s-stained paraﬃn sections. The mesangial expansion is shown by arrows and hyaline casts by(c) in the renal tubules in untreated
rats only.Mediators of Inﬂammation 5
Table 1: General physiology†.
Treatment Weight gain (g/14
weeks)
24-hour water intake
(ml/d)
24-hour urine volume
(ml/d)
24-hour urine volume
(ml/g kidney weight/d)
Serum triglycerides
(mg/ml)
Lean Control 124 ± 56 1 ± 34 8 ± 1 116 ± 41 . 4 4 ± 0.56
Lean CAN 119 ± 15 5 ± 14 2 ± 2∗ 104 ± 61 . 0 8 ± 0.07
Obese Control 232 ± 14∗ 73 ± 3∗ 51 ± 27 5 ± 3∗ 5.74 ± 0.95∗
Obese CAN 191 ± 20∗ 107 ± 17∗# 69 ± 7∗# 107 ± 14# 2.66 ± 0.41#
Factors Results of 2-way ANOVA for above parameters (P-values)
Body Type <.001 <.001 <.001 .028 <.001
Treatment .065 .074 .174 .024 .013
Interaction .145 .016 .006 <.001 .044
†mean ± sem, n = 7o r8 / g r o u p ;∗indicates a signiﬁcant diﬀerence from lean control; #indicates a signiﬁcant diﬀerence between obese control and obese
CAN groups, by unpaired t-test. In bold- P-values <. 05 by 2-way ANOVA (signiﬁcant).
In addition, ﬁnal blood glucose levels (measured just
prior to euthanization at 14 weeks) trended toward being
higher in obese rats treated with CAN relative to all
other groups (Figure 3(b)), P-value = .07, as compared
to lean control). Plasma insulin levels (Figure 3(c))w e r e
signiﬁcantly higher in the obese rats, and not altered by CAN
in either lean or obese.
3.5. Eﬀects of Long-Term Candesartan Treatment on the
Cytokine Proﬁle in Kidney Tissue. Renal levels of only two
cytokines (out of 14) were elevated in obese versus lean
rats in the control state, that is, MCP-1 and IL-1β(Figures
4(a) and 4(b)).Their levels were, respectively. 200% and
70% higher than untreated lean controls. Long-term CAN
treatment reduced these levels in obese rats such that they
wereno longersigniﬁcantlydiﬀerentthanlean.Therewasno
signiﬁcant eﬀect of CAN on the level of these two cytokines
in the lean rats.
Surprisingly,thekidneylevelsof9outofthe14cytokines
were signiﬁcantly lower in the untreated obese Zucker rats
relative to lean controls. These were IFN-γ, IL-4, IL-2, IL-
6, GM-CSF, IL-1α, IL-10, IL-12p70, and TNF-α (Figures 4
and 5). Some of these data are depicted as individual rat
values (rather than means) because the protein was “below
the level of detection” in some animals (Figure 5). Long-
term CAN treatment increased the level of these proteins,
suchthattheywerenolongersigniﬁcantlydiﬀerentfromlean
control levels (except for IFN-γ, Figure 5(a),which remained
signiﬁcantly lower in CAN-treated obese rats). Similar to
whatwasobservedforMCP-1andIL-1β,CANhadnoeﬀects
on the levels of these 9 cytokines in the lean rats.
Finally, a diﬀerent pattern emerged for renal levels of
IL-18 and GRO-KC (Figure 4). These 2 cytokines were
not signiﬁcantly diﬀerent between lean and obese rats, but
increased by CAN treatment in obese rats only, so that
the levels were elevated (relative to obese control rats). No
signiﬁcant diﬀerences were observed for IL-5 levels between
any of the groups.
3.6. Eﬀects of Candesartan Therapy on eNOS and TGF-β.
In Figure 6, we show renal expression of endothelial nitric
oxide synthase (eNOS), a protein central in oxidative-stress
relatedpathwaysduetoitsgenerationofnitricoxide[38]and
transforming growth factor β, a protein central in increased
matrix formation and deposition in diabetic nephropathy
[39]. Both eNOS and TGF-β were expressed at greatest levels
in obese CAN-treated rats. Moreover, there was a signiﬁcant
interactive term for both proteins in that CAN reduced
expression in lean rats but increased it in the obese.
4. Discussion
We have demonstrated that chronic candesartan treatment
attenuated renal pathology and reduced renal levels of MCP-
1a n dI L - 1 β in obese rats. Consistently, it markedly improved
renal function and lowered serum triglyceride levels in
these rats. Unexpectedly, glucose tolerance was worsened.
Moreover, renal levels of 11 out of 14 cytokine analyzed were
in fact signiﬁcantly increased by CAN in the obese rats. IL-18
and GRO-KC levels were highest in CAN-treated obese rats
ascomparedtoallothergroups.Overall,ourresultsfromthe
cytokine array suggest that the regulation of renal cytokine
levels by chronic candesartan-treatment of obese Zucker rats
appeared to be primarily driven by normalization of kidney
function and architecture and perhaps preservation of these
necessary and sometimes protective inﬂammatory pathways.
Decreases in serum triglyceride and/or renal MCP-1 and IL-
β levels may have a role in the reno-protective actions of
candesartan in the metabolic syndrome.
In many models of diabetes and insulin resistance,
elevated RAS activity has been shown to be intimately
intertwined with activation of inﬂammatory pathways in
renal tissue [40]. In contrast to expectations, examining
wholekidneyhomogenates,wefoundanincreaseinonlytwo
cytokines, IL-1β and MCP-1 in the obese Zucker rat kidneys,
relative to lean controls. Increased mRNA expression of
TNF-α, IL-1 and IL-6 has been reported in the kidney of
streptozotocin-induced type 1 diabetic rats [41] ,am o d e l
associated with much higher levels of plasma glucose and
no obesity. Less information is available with regard to renal
levels of cytokines in models of the metabolic syndrome
or type II diabetes. Xu et al. [42] found increased mRNA
expression for 2 cytokines, MCP-1 and IL-6, in renal cortical
tissue obtained from similarly aged obese Zucker rats. These6 Mediators of Inﬂammation
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Figure 3: Metabolic function: (a) Glucose-tolerance test (GTT) performed in candesartan-treated (CAN) or untreated (c) lean and obese
rats at 13 weeks of treatment (n = 8 per body type/treatment). Blood glucose levels measured at diﬀerent time points in response to 50%
dextrose solution (3 ml/kg · bw) given intraperitoneally. Area under the curve was higher for the obese rats compared to the lean, and a
signiﬁcant interaction was found between body type and treatment by 2-way ANOVA (P<. 05). (b) Blood glucose and (c) plasma insulin
levelsattheendof14weeksoftreatment(n = 8perbodytype/treatment)werediﬀerentbetweenthebodytypesby2-wayANOVA(P<. 05);
14 weeks of CAN treatment did not aﬀect these levels. ∗ indicates a signiﬁcant diﬀerence (P<. 05) from lean control mean and # from obese
control mean, by unpaired t-test.
levels were reduced by losartan (another ARB). In our study,
we conﬁrmed the increase at the protein level for MCP-
1; however, we showed a decrease in IL-6 protein levels.
In our rats, both of these cytokines were normalized by
CAN. The diﬀerence between our study and that of Xu et
al. [42] may have resulted from the diﬀerence in mRNA
versus protein, or in the fact that we evaluated whole kidney,
rather than only cortex. Another possibility is that the
severity of the nephropathy may have aﬀected the expression
pattern. It is unclear whether their rats or ours had greater
severity of renal disease at the time when samples were
collected.Mediators of Inﬂammation 7
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Figure 4: Mean kidney cytokine levels (all rats detectable)
(a) higher level cytokines including: monocyte chemotactic
protein-1 (MCP1), interleukin-2 (IL-2), interleukin-6 (IL-6), and
interleukin-18 (IL-18); (b) lower level cytokines including: inter-
leukin 1β(IL-1β), granulocyte macrophage colony-stimulating-
factor (GM-CSF), growth regulated oncogene (GRO-KC), and
interleukin-5 (IL-5) in whole kidney tissue homogenate from
candesartan treated (CAN) or untreated (C) lean and obese rats at
the end of 14 weeks of treatment (n = 8 per body type/treatment).
∗indicatesasigniﬁcantdiﬀerence(P<. 05)fromleancontrolmean
and # from obese control mean, by unpaired t-test.
Overall, including IL-6, we found 9 cytokines that
were signiﬁcantly reduced in obese versus lean rat kidney.
We suggest that renal protein levels of some cytokines or
chemokines may actually decline with loss of epithelial cells
and the progression of renal disease. In agreement, Waldherr
et al. [43] reported that TNF-α,I F N - γ and IL-2 levels in the
glomeruli were undetectable in the chronic form of human
glomerulonephritis, while their levels were signiﬁcantly
increased in the acute form of the disease. Furthermore,
a study examining the relationship between the expression
of IL-6 mRNA and the degree of glomerular mesangial
expansion in human diabetic nephropathy demonstrated
that signal intensity for IL-6 mRNA was strongest in tissues
from moderate mesangial expansion but was weak in those
from mild and severe mesangial expansion [44]. These and
our studies support the possibility that as renal disease
progresses there is decompensation at the cellular level in the
immune response, perhaps due to architectural or ﬁbrotic
changes. Further studies will be needed to address this
possibility.
In further support of this hypothesis was the fact that
a full 11 out of 14 cytokines in the obese rats were
signiﬁcantly diﬀerent from lean rats in the untreated state
and basically restored, or at least partially restored, by CAN.
CAN attenuated renal damage, at least as gauged by reduced
collagen and glycogen deposition and plasma creatinine.
Furthermore, CAN had no signiﬁcant eﬀects on the lean
rat cytokine proﬁle, diminishing the possibility that other
factors, for example, the fall in blood pressure with CAN as
shown by us previously in both lean and obese rats [24], had
any direct role on cytokine/chemokine levels.
Nevertheless, IL-18 and GRO-KC (which were not dif-
ferent between untreated lean and obese) were signiﬁcantly
increased in the treated obese rats only. We believe that
hyperglycemia and/or slower plasma glucose clearance could
be responsible for increased expression of these cytokines.
H i g hg l u c o s el e v e l sh a v eb e e nd e m o n s t r a t e dt oi n c r e a s et h e
s e c r e t i o no fb o t hI L - 1 8a n dG R O - K C[ 45]. Moreover, we
showed that CAN treatment increased renal expression of
transforming growth factor β1( T G F - β1), but again, only in
the obese rats. A potentially causative relationship between
these two variables was recently demonstrated by Bani-
Hani et al. [46]in IL-18-overexpressing mice; that is, TGF-
β1 expression was reduced when IL-18 was neutralized by
antibodies. IL-18 may have a facilitative role in glucose
utilization by cells. Using IL-18 knockout mice, it has been
demonstrated that lack of endogenous IL-18 results in
obesity, insulin resistance, and hyperglycemia [47]. Further-
more, increased serum levels of IL-18 have been associated
with insulin resistance and obesity in humans [48–50].
It is nevertheless somewhat surprising that TGF-β1w a s
increased quite dramatically in the obese CAN-treated rats,
relative to all other groups, while our other evidence points
to reduced epithelial-to-mesenchymal transition (EMT) and
the development of ﬁbrotic renal disease in obese rats with
CAN treatment. It is possible that CAN simply delays renal
disease in the obese Zucker rat and that increased TGF-1β
maybetransitoryandoccurredatanearliertime-pointinthe
obese control rats. It is also possible that CAN is protective
at a step down-stream of TGF-β1 with regard to matrix
accumulation. Additional studies would need to be done to
clarify this matter.
If we accept the possibility that CAN may have increased
GRO-KC,IL-18, and TGF-β1 as a result of relative hyper-
glycemia in these rats, what was the mechanism for the
impaired GTT? In fact, some evidence to contrary exists with
regard to predicted systemic eﬀects of AT1R blockade. ARBs,
often prescribed to hypertensive subjects with the metabolic
syndrome, have been demonstrated in several clinical studies
to reduce the number of new onset cases of type II diabetes
[51],improveglucosetolerance,andmaypreventprogressive
beta-cell failure in diabetes [52, 53]. Tikellis et al.[53]found
improved pancreatic islet morphology in Zucker diabetic8 Mediators of Inﬂammation
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Figure 5: Individual kidney cytokine level (some rats undetectable) (a) interferon-γ (IFN-γ) (b) interleukin-4 (IL-4), (c) interleukin-1α
(IL-1α), (d) interleukin 10 (IL-10), (e) interleukin 12p70, and (f) tumor necrosis factor α (TNF-α) in whole kidney tissue homogenate from
candesartan-treated (CAN) or -untreated (c) lean and obese rats at the end of 14 weeks of treatment (n = 8 per body type/treatment).
∗ indicates a signiﬁcant diﬀerence, P<. 05, from lean control mean and # from obese control mean, by rank test on categorical assignments.Mediators of Inﬂammation 9
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Figure 6: Western blotting of whole kidney eNOS and TGF-β. Representative immunoblot of whole kidney homogenates from -candesartan
treated (CAN) or-untreated (C) lean and obese rats at the end of 14 weeks of treatment probed with (a) eNOS and (b) TGF-β antibodies,
respectively. Equal amounts of total protein were loaded in each lane and each lane is loaded with a sample from a diﬀerent rat. Below each
blots is its densitometry summary (n = 6 rats/group). Results were analyzed by 2-way ANOVA and also by t-test. ∗indicates a signiﬁcant
diﬀerence (P<. 05) from lean control mean and # from obese control mean, by unpaired t-test.
fatty rats (ZDF), a substrain of the Zucker rat, that develops
type II diabetes extremely early, after treatment with irbe-
sartan (an ARB) or perindopril (an angiotensin converting
enzyme inhibitor). Furthermore, candesartan was shown to
improve GTT in high-fat fed Wistar rats [54]. These rats
had increased expression of the peroxisomal proliferator
activated receptor, subtype γ (PPAR-γ) in liver and adipose
tissue, which they proposed may have been the mechanism
for candesartan’s eﬀects [54].
Nonetheless, there are some clinical trials of 5 months
and longer, in diabetic patients, which in agreement with our
ﬁndings showed no improvement in metabolic parameters,
including glucose tolerance with chronic ARB therapy [55–
58]. In our study, the diﬀerences between treated- and
untreated-obese rats were not large; in fact ﬁnal blood glu-
cose and insulin levels trended higher with CAN treatment,
but were not statistically diﬀerent and highly variable. What
isclearisthattheywerenotimproved.However,surprisingly,
GTT was signiﬁcantly improved in the lean rats. Therefore,
o n l yo b e s er a t sr e s p o n d e di nt h i ss o m e w h a tn e g a t i v ef a s h i o n
to chronic CAN therapy with regard to GTT. Glucose dose
was administered intraperitoneally (ip) according to weight
of the rats, but there were no signiﬁcant diﬀerences in body
weight between CAN-treated and control obese rats at the
time of the GTT. It is possible that the lower BP in the
CAN-treated rats somehow resulted in delayed uptake from
the ip cavity, with subsequent delay in clearance. The blood
glucose levels in the CAN-treated obese rats did not peak
until 1.5 hours, while they were at their peak in the control
obese rat at 30 minutes (Figure 3). However, the fall in
BP in the lean rats did not aﬀect time-of-peak for glucose,
which occurred at the same time (15 minutes) for lean
control and lean CAN-treated rats. It is possible that chronic
CAN treatment negatively impacted the pancreatic release of
insulinintheobeserats,forexample,asaresultofthelowBP.
Insulin levels were not measured during the GTT challenge;
however, in the basal state they were higher (not lower)
than control obese rats, suggesting relatively greater insulin
resistance in these rats with the ability to compensate with
hyperinsulinemia still intact. Thus, it appeared that they may
have been more insulin resistant at the level of peripheral
tissues.
Candesartan-treated obese rats also exhibited relative
polyuria and polydipsia, despite improvement in many his-
tologicalfeaturesofthekidney,andingeneralrenalfunction.
Increased urine volumes could be due to glucose-induced
osmotic diuresis in the CAN-treated obese rats, further
supporting impaired glucose handling and insulin resistance
in these rats. In contrast, lean rats treated with CAN showed
the opposite; that is, they had signiﬁcantly reduced urine
volumes with CAN. The mechanism(s) underlying reduced
urine volume with CAN treatment in these lean rats is also
unknown. Ang II has been shown to stimulate thirst via
AT1R in the brain. Candesartan administered peripherally
has been shown to block this eﬀect [59]. Thus, it is possible
that this is the mechanism underlying reduced water intake
in the lean rats. We might speculate that this eﬀect was
masked in the obese due to thirst generated as a result of the
osmotic diuresis.
Overall, CAN therapy was protective of the kidney both
functionally and histologically. CAN was able to restore or
normalize (to lean levels) aberrant renal levels of 11 of 14
cytokines measured. This may be critical in the continuation
of adequate immune function in the kidney of the obese
rat. In contrast to obese rats, CAN had no eﬀects on
renal cytokine levels in lean rats. Moreover, these protective10 Mediators of Inﬂammation
changes occurred despite candesartan’s propensity to worsen
glucose tolerance in the obese rats. Impaired GTT and
increased levels of renal IL-18, GRO-KC, and TGF-β1 in the
CAN-treated obese rats were puzzling, but of clear concern.
The mechanisms underlying these eﬀects require additional
study.
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